Objective: This systematic review and meta-analysis aimed to evaluate whether dyslipidemia affects the mortality and severity of COVID-19, we also aimed to evaluate whether other comorbidities influence the association Methods: A systematic literature search using PubMed, Embase, and EuropePMC was performed on 8 October 2020 This study's main outcome is a poor composite outcome, comprising of mortality and severe COVID-19 Results: There were 9 studies with 3663 patients The prevalence of dyslipidemia in this pooled analysis was 18% (4%-32%) Dyslipidemia was associated with increased composite poor outcome (RR 1 39 [1 02, 1 88], P = 010;I 2: 56 7%, P = 018) Subgroup analysis showed that dyslipidemia was associated with severe COVID-19 (RR 1 39 [1 03, 1 87], P = 008;I 2: 57 4%, P = 029) Meta-regression showed that the association between dyslipidemia and poor outcome varies by age (coefficient: −0 04, P = 033), male gender (coefficient: −0 03, P = 042), and hypertension (coefficient: −0 02, P = 033), but not diabetes (coefficient: −0 24, P = 135) and cardiovascular diseases (coefficient: −0 01, P = 506) Inverted funnel-plot was relatively symmetrical Egger's test indicates that the pooled analysis was not statistically significant for small-study effects (P = 206) Conclusion: Dyslipidemia potentially increases mortality and severity of COVID-19 The association was stronger in patients with older age, male, and hypertension PROSPERO Registration Number: CRD42020213491
Dyslipidemia Increases the Risk of Severe COVID-19: A Systematic Review, Meta-analysis, and Meta-regression